Overview Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease Status: Completed Trial end date: 2017-12-01 Target enrollment: Participant gender: Summary This is a pharmacodynamics study of emixustat hydrochloride in subjects with macular atrophy secondary to Stargardt disease. Phase: Phase 2 Details Lead Sponsor: Acucela Inc.Kubota Vision Inc.